About RxCelerate
RxCelerate is a leading drug discovery and development platform. We are driven by a mission to improve patients’ lives through scientific excellence and innovation.
We focus on solving complex scientific challenges based on first principles, working out our clients’ specific needs to get their potential drug to the clinic. Rather than fitting to existing models, we specialise in bespoke experimental design with data-rich endpoints, maximising the chances of clinical success while reducing long-term costs.
Our highly talented team of scientists bring expertise across the entire drug discovery pathway. By combining integrated teams with our unique technologies, we’ll design the right strategy to drive your asset through drug discovery, preclinical research and beyond.
Cutting-edge technologies
These include RxNfinity™ for rapid in silico screening, the Galaxy® platform for generating diverse ‘clinic-ready’ antibodies, and ProQuant® for precise bottom-up proteomics across diverse biological samples.
Comprehensive services
We cover the entire discovery and development spectrum, including in silico design and discovery, antibody discovery, synthetic and medicinal chemistry, in vitro services, preclinical services, and project management.
Bespoke and flexible experimental design
We de-risk assets through real-time data analysis and collaborative strategic thinking. Enabling informed, intelligent decisions for efficient, well-executed iterative experiments.
Our Mission
We believe in scientific excellence, based on first principles, that creates maximal value when paired with cost and operational efficiency. Every client project is unique and our bespoke design and approach is centered on de-risking the asset through real-time data analysis and collaborative strategic thinking, which allows for informed and intelligent decision making throughout the drug development process.
Our Impact In Numbers
Over the last ten years RxCelerate has contributed to…
25+
clinical candidates
14
drugs in the clinic
Who we work with…
75%
repeat business
1/3
of our client base are virtual
Our Background
RxCelerate is the realisation of a shared vision by its founders, David Grainger and Jill Reckless. With a partnership that spans almost 30 years, their journey began at Cambridge University, where they worked together under Professor Jim Metcalfe’s guidance. During this time, they noticed that the resources and infrastructure needed for innovative drug development were often out of reach for smaller, independent groups, leaving valuable ideas unexplored. In 2011, David’s experience at Index Ventures (later Medicxi) highlighted similar challenges faced by biotech startups. So, in April 2013, they founded RxCelerate to fill this gap, creating a platform covering every aspect of drug discovery and development. Today, the RxCelerate team has grown to over a hundred experts, all driven by the mission to democratise drug discovery and development, making it accessible to anyone with a promising idea.
RxCelerate offers a unique business model catering to both small molecules and biologics. We work with you to drive your asset through drug discovery, preclinical research and beyond.
Our combination of integrated teams and unique technologies allows RxCelerate to develop the optimal drug discovery strategy to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional approaches.